Cargando…
Using Biomarkers to Inform Cumulative Risk Assessment
BACKGROUND: Biomarkers are considered the method of choice for determining exposure to environmental contaminants and relating such exposures to health outcomes. However, the association between many biomarkers and outcome is not direct because of variability in sensitivity and susceptibility in the...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
National Institute of Environmental Health Sciences
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867975/ https://www.ncbi.nlm.nih.gov/pubmed/17520075 http://dx.doi.org/10.1289/ehp.9334 |
_version_ | 1782133359178153984 |
---|---|
author | Ryan, P. Barry Burke, Thomas A. Cohen Hubal, Elaine A. Cura, Jerome J. McKone, Thomas E. |
author_facet | Ryan, P. Barry Burke, Thomas A. Cohen Hubal, Elaine A. Cura, Jerome J. McKone, Thomas E. |
author_sort | Ryan, P. Barry |
collection | PubMed |
description | BACKGROUND: Biomarkers are considered the method of choice for determining exposure to environmental contaminants and relating such exposures to health outcomes. However, the association between many biomarkers and outcome is not direct because of variability in sensitivity and susceptibility in the individual. OBJECTIVES: We explore the relationship between environmental exposures and health outcomes as mitigated by differential susceptibility in individuals or populations and address the question “Can biomarkers enable us to understand and quantify better the population burden of disease and health effects attributable to environmental exposures?” METHODS: We use a case–study approach to develop the thesis that biomarkers offer a pathway to disaggregation of health effects into specific, if multiple, risk factors. We offer the point of view that a series or array of biomarkers, including biomarkers of exposure, biomarkers of susceptibility, and biomarkers of effect, used in concert offer the best means by which to effect this disaggregation. We commence our discussion by developing the characteristics of an ideal biomarker, then give some examples of commonly used biomarkers to show the strengths and weaknesses of current usage. We follow this by more detailed case-study assessment outlining the state-of-the-science in specific cases. We complete our work with recommendations regarding the future use of biomarkers and areas for continued development. CONCLUSIONS: The case studies provide examples of when and how biomarkers can be used to infer the source and magnitude of exposure among a set of competing sources and pathways. The answer to this question is chemical specific and relates to how well the biomarker matches the characteristics of an “ideal” biomarker–in particular ease of collection and persistence. The use of biomarkers in combination provides a better opportunity to disaggregate both source and pathway contributions. |
format | Text |
id | pubmed-1867975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | National Institute of Environmental Health Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-18679752007-06-07 Using Biomarkers to Inform Cumulative Risk Assessment Ryan, P. Barry Burke, Thomas A. Cohen Hubal, Elaine A. Cura, Jerome J. McKone, Thomas E. Environ Health Perspect Research BACKGROUND: Biomarkers are considered the method of choice for determining exposure to environmental contaminants and relating such exposures to health outcomes. However, the association between many biomarkers and outcome is not direct because of variability in sensitivity and susceptibility in the individual. OBJECTIVES: We explore the relationship between environmental exposures and health outcomes as mitigated by differential susceptibility in individuals or populations and address the question “Can biomarkers enable us to understand and quantify better the population burden of disease and health effects attributable to environmental exposures?” METHODS: We use a case–study approach to develop the thesis that biomarkers offer a pathway to disaggregation of health effects into specific, if multiple, risk factors. We offer the point of view that a series or array of biomarkers, including biomarkers of exposure, biomarkers of susceptibility, and biomarkers of effect, used in concert offer the best means by which to effect this disaggregation. We commence our discussion by developing the characteristics of an ideal biomarker, then give some examples of commonly used biomarkers to show the strengths and weaknesses of current usage. We follow this by more detailed case-study assessment outlining the state-of-the-science in specific cases. We complete our work with recommendations regarding the future use of biomarkers and areas for continued development. CONCLUSIONS: The case studies provide examples of when and how biomarkers can be used to infer the source and magnitude of exposure among a set of competing sources and pathways. The answer to this question is chemical specific and relates to how well the biomarker matches the characteristics of an “ideal” biomarker–in particular ease of collection and persistence. The use of biomarkers in combination provides a better opportunity to disaggregate both source and pathway contributions. National Institute of Environmental Health Sciences 2007-05 2007-01-24 /pmc/articles/PMC1867975/ /pubmed/17520075 http://dx.doi.org/10.1289/ehp.9334 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright. |
spellingShingle | Research Ryan, P. Barry Burke, Thomas A. Cohen Hubal, Elaine A. Cura, Jerome J. McKone, Thomas E. Using Biomarkers to Inform Cumulative Risk Assessment |
title | Using Biomarkers to Inform Cumulative Risk Assessment |
title_full | Using Biomarkers to Inform Cumulative Risk Assessment |
title_fullStr | Using Biomarkers to Inform Cumulative Risk Assessment |
title_full_unstemmed | Using Biomarkers to Inform Cumulative Risk Assessment |
title_short | Using Biomarkers to Inform Cumulative Risk Assessment |
title_sort | using biomarkers to inform cumulative risk assessment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867975/ https://www.ncbi.nlm.nih.gov/pubmed/17520075 http://dx.doi.org/10.1289/ehp.9334 |
work_keys_str_mv | AT ryanpbarry usingbiomarkerstoinformcumulativeriskassessment AT burkethomasa usingbiomarkerstoinformcumulativeriskassessment AT cohenhubalelainea usingbiomarkerstoinformcumulativeriskassessment AT curajeromej usingbiomarkerstoinformcumulativeriskassessment AT mckonethomase usingbiomarkerstoinformcumulativeriskassessment |